Literature DB >> 11114265

FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.

W Xia1, B L Ostaszewski, W T Kimberly, T Rahmati, C L Moore, M S Wolfe, D J Selkoe.   

Abstract

To investigate the mechanism of regulation of Ass production by familial Alzheimer's disease (FAD)-linked presenilin 1 (PS1), we used a cell-free system that allows de novo Ass generation to examine whether PS1 participates directly in the gamma-secretase reaction. Optimal Ass generation in vitro was achieved at mildly acidic pH and could be inhibited by the aspartyl protease inhibitor pepstatin A, consistent with the suggestion that gamma-secretase is an aspartyl protease. Dominant negative mutations of the critical transmembrane aspartates in PS1 or full deletion of PS1 did not alter the maturation of APP in the secretory pathway. Instead, PS1 had a direct effect on the inhibition of Ass production by a designed peptidomimetic inhibitor: the inhibition was significantly less effective in cells expressing FAD-causing mutations in either APP or PS1 than in cells expressing the wild-type proteins. Taken together, these findings suggest that PS1 participates physically in a complex with APP during the gamma-secretase cleavage event. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114265     DOI: 10.1006/nbdi.2000.0322

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  20 in total

Review 1.  Presenilin, Notch, and the genesis and treatment of Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 2.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.

Authors:  Can Zhang; Andrew Browne; Doo Yeon Kim; Rudolph E Tanzi
Journal:  Curr Alzheimer Res       Date:  2010-02       Impact factor: 3.498

4.  Intramembrane proteolysis of β-amyloid precursor protein by γ-secretase is an unusually slow process.

Authors:  Frits Kamp; Edith Winkler; Johannes Trambauer; Amelie Ebke; Regina Fluhrer; Harald Steiner
Journal:  Biophys J       Date:  2015-03-10       Impact factor: 4.033

5.  Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N141I): correlation of selenoprotein M with Alzheimer's disease.

Authors:  Dae Y Hwang; Jung S Cho; Jae H Oh; Sun B Shim; Seung W Jee; Su H Lee; Su J Seo; Sang-Koo Lee; Seok H Lee; Yong K Kim
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

6.  Changes in presenilin 2-binding Wnt proteins, behavior, amyloid-beta 42, gamma-secretase activity, and testosterone sensitivity in transgenic mice coexpressing tetracycline-controlled transactivator and human mutant presenilin 2.

Authors:  Dae Y Hwang; Jung S Cho; Chuel K Kim; Sun B Shim; Seung W Jee; Su H Lee; Su J Seo; Soo Y Choi; Yong K Kim
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 7.  Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits.

Authors:  M P Mattson; S L Chan
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 9.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

Review 10.  Impact of amyloid imaging on drug development in Alzheimer's disease.

Authors:  Chester A Mathis; Brian J Lopresti; William E Klunk
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.